The estimated Net Worth of Sara Kenkare Mitra is at least $2.11 Million dollars as of 3 September 2024. Dr Mitra owns over 13,926 units of Alector stock worth over $1,694,864 and over the last 3 years he sold ALEC stock worth over $416,040.
Dr has made over 7 trades of the Alector stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 13,926 units of ALEC stock worth $67,959 on 3 September 2024.
The largest trade he's ever made was selling 13,926 units of Alector stock on 3 September 2024 worth over $67,959. On average, Dr trades about 7,025 units every 55 days since 2022. As of 3 September 2024 he still owns at least 291,715 units of Alector stock.
You can see the complete history of Dr Mitra stock trades at the bottom of the page.
Dr. Sara Kenkare-Mitra Ph.D. is the Pres and Head of R&D at Alector.
Sara's mailing address filed with the SEC is C/O ALECTOR, INC., 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 5 years, insiders at Alector have traded over $148,873,269 worth of Alector stock and bought 20,000 units worth $500,000 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Advisors Llc Orbi Med Capit..., and Terrance Mcguire. On average, Alector executives and independent directors trade stock every 17 days with the average trade being worth of $438,922. The most recent stock trade was executed by Marc Grasso on 3 September 2024, trading 7,297 units of ALEC stock currently worth $35,609.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Alector executives and other stock owners filed with the SEC include: